The Clinical Services Core of the CNMD represents a unique resource that is organized around the recruitment and characterization of unmedicated schizophrenic subject at both early and later phases of the illness. Such subjects represent an extremely limited and important patient population. Specifically, the Clinical Services Core: 1) screens, recruits and assesses subjects using standardized assessment methods found in the Core Assessment Battery in order to generate a uniform data base shared by all investigators; 2) provides reliable and valid diagnostic evaluation using a well-developed longitudinal methodology and initial clinical follow-up and care; 3) utilizes well developed policies and procedures to coordinate a range of protocols and avoid duplication of efforts; and 4) Provides clinical and diagnostic expertise for postmortem diagnostic conference for the Human Brain Bank Core-B. Because the Clinical Services Core integrates and coordinates the recruitment and assessment of subjects, Projects 7- Cohen and 8-Sweeney in the CNMD and other funded collaborating investigators shares these subjects efficiently and productively. The Clinical Services Core also relies on the Statistics and Data Management Core-D to provide data management for the Core Assessment Battery.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Specialized Center (P50)
Project #
5P50MH045156-13
Application #
6615247
Study Section
Project Start
2002-07-01
Project End
2003-06-30
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
13
Fiscal Year
2002
Total Cost
$228,564
Indirect Cost
Name
University of Pittsburgh
Department
Type
DUNS #
053785812
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Cai, HuaLin; Zhou, Xiang; Dougherty, George G et al. (2018) Pregnenolone-progesterone-allopregnanolone pathway as a potential therapeutic target in first-episode antipsychotic-naïve patients with schizophrenia. Psychoneuroendocrinology 90:43-51
Stevenson, J M; Reilly, J L; Harris, M S H et al. (2016) Antipsychotic pharmacogenomics in first episode psychosis: a role for glutamate genes. Transl Psychiatry 6:e739
Lizano, Paulo L; Keshavan, Matcheri S; Tandon, Neeraj et al. (2016) Angiogenic and immune signatures in plasma of young relatives at familial high-risk for psychosis and first-episode patients: A preliminary study. Schizophr Res 170:115-22
Bishop, Jeffrey R; Reilly, James L; Harris, Margret S H et al. (2015) Pharmacogenetic associations of the type-3 metabotropic glutamate receptor (GRM3) gene with working memory and clinical symptom response to antipsychotics in first-episode schizophrenia. Psychopharmacology (Berl) 232:145-54
Horton, Leslie E; Tarbox, Sarah I; Olino, Thomas M et al. (2015) Trajectories of premorbid childhood and adolescent functioning in schizophrenia-spectrum psychoses: A first-episode study. Psychiatry Res 227:339-46
Hall, Nathan; Colby, Carol (2014) S-cone visual stimuli activate superior colliculus neurons in old world monkeys: implications for understanding blindsight. J Cogn Neurosci 26:1234-56
Subramanian, Janani; Colby, Carol L (2014) Shape selectivity and remapping in dorsal stream visual area LIP. J Neurophysiol 111:613-27
Berdyyeva, Tamara K; Olson, Carl R (2014) Intracortical microstimulation of supplementary eye field impairs ability of monkeys to make serially ordered saccades. J Neurophysiol 111:1529-40
Lencer, Rebekka; Bishop, Jeffrey R; Harris, Margret S H et al. (2014) Association of variants in DRD2 and GRM3 with motor and cognitive function in first-episode psychosis. Eur Arch Psychiatry Clin Neurosci 264:345-55
Richard, Annette E; Carter, Cameron S; Cohen, Jonathan D et al. (2013) Persistence, diagnostic specificity and genetic liability for context-processing deficits in schizophrenia. Schizophr Res 147:75-80

Showing the most recent 10 out of 382 publications